Prelude Capital Management, LLC Iovance Biotherapeutics, Inc. Transaction History

Prelude Capital Management, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$3.3 - $8.89 $39,600 - $106,680	12,000 New	12,000 $97,000
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $256,785 - $381,695	46,435 New	46,435 $283,000
Q1 2021 May 17, 2021	SELL	$28.67 - $52.59 $128,470 - $235,655	-4,481 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $149,313 - $267,634	-5,325 Reduced 54.3%	4,481 $208,000
Q3 2020 Nov 16, 2020	SELL	$27.75 - $36.3 $51,393 - $67,227	-1,852 Reduced 15.89%	9,806 $323,000
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $96,840 - $145,919	3,559 Added 43.94%	11,658 $320,000
Q1 2020 May 15, 2020	SELL	$19.54 - $38.85 $130,312 - $259,090	-6,669 Reduced 45.16%	8,099 $242,000
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $1,346 - $2,205	75 Added 0.51%	14,768 $409,000
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $263,247 - $380,458	14,633 Added 24388.33%	14,693 $267,000
Q2 2019 Aug 14, 2019	BUY	$9.78 - $24.52 $586 - $1,471	60 New	60 $1,000
Q4 2018 Feb 14, 2019	SELL	$7.51 - $11.93 $41,305 - $65,615	-5,500 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$11.25 - $17.7 $28,125 - $44,250	-2,500 Reduced 31.25%	5,500 $62,000
Q2 2018 Aug 14, 2018	SELL	$12.45 - $16.95 $31,125 - $42,375	-2,500 Reduced 23.81%	8,000 $102,000
Q1 2018 May 15, 2018	BUY	$8.1 - $19.5 $4,050 - $9,750	500 Added 5.0%	10,500 $177,000
Q4 2017 Feb 14, 2018	BUY	$6.65 - $9.25 $16,625 - $23,125	2,500 Added 33.33%	10,000 $80,000
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $33,375 - $64,125	7,500	7,500 $58,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.35B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.